Olema Pharmaceuticals, Inc.
$10.45
The Read: Olema’s stock has historically declined sharply—up to about 13%—after in-line earnings reports that lacked new clinical progress or partnerships, with only modest gains following isolated positive Phase 1 data announcements.
Price
Overlays
Panel
OLMA
Hover to view data
No Data